Shuang Ho Hospital
New Taipei City, Taiwan
NCT Number: NCT04555941
Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique that is increasingly used for a growing number of research and clinical applications.Typically, this transient magnetic field is focally applied with a figure-of-eight coil that is carefully placed on the surface of the scalp over a targeted stimulation site. Patterned repetitive TMS (rTMS), such as theta burst stimulation (TBS) can produce long-lasting effects on neural activity and behavior beyond the stimulation period (Chou et al., 2015a; Fitzgerald et al., 2006). In general, high frequency (> 5 Hz) rTMS and its newer version, intermittent theta burst stimulation (iTBS), facilitate cortical excitability, whereas low frequency (about 1 Hz) rTMS and continuous theta burst stimulation contribute to opposite effects (Pascual-Leone et al., 2000; Huang et al., 2005; Wassermann and Zimmermann, 2012).Careful manipulation of the parameters comprising these patterned rTMS pulse trains can induce neuroplastic changes that resemble either long-term potentiation (LTP) or depression (Chen et al., 1997; Pascual-Leone et al., 1994). Early studies targeting the motor cortex helped elucidate which rTMS parameters promote particular responses and their neurophysiological underpinnings (Klomjai et al., 2015).
In recent years, rTMS has been closely investigated to evaluate its potential to modulate cognitive functions in Alzheimer'sdisease (AD) and mild cognitive impairment (MCI). As compared to conventional excitatory rTMS protocols, iTBS leads to comparable effects with similar number of pulses but considerable shorter duration and lower intensity of stimulation (Bakker et al., 2015; Rossi, Hallett, Rossini, Pascual-Leone, & Safety, 2009). Recent literature also suggest that TBS has lower rates of reported adverse event (AE) compared to rTMS (Najib & Horvath, 2014). Therefore, iTBS is assumed to modulate cognitive function in people with cognitive impairments.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Interventional
Phase 2
New Taipei City, Taiwan
Visit 1: Informed Consent, Brain MRI/Neuropsychological Battery
Visit 2-11: (up to a week after visit 1) iTBS - or Sham-Treatment (10 sessions, 80% Resting Motor Threshold, 2s stimulation 8s inter-stimulus interval per train, 20 trains per block, 3 blocks per session with a 5-min break, 1 session per day)
Visit 12: (1 day or same day after visit 11) Functional Brain MRI/Neuropsychological Battery
Visit 13: (4 weeks after visit 11) Functional Brain MRI/Neuropsychological Battery
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
active or Sham iTBS will be given to the AD/MCI patient
Other names: Magstim rapid 2
Time frame: Baseline, immediate post-iTBS, follow-up (4 weeks post-iTBS)
WAIS-IV short-form, Word Sequence Learning Test, Benton Visual Retention Test, Color Trial Tests, 3-D Dimensional Constructional Test, Visual Confrontation Naming, Semantic Verbal Fluency Test, Stroop Color-Word Test
Time frame: Baseline, immediate post-iTBS, follow-up (4 weeks post-iTBS)
Change in white matter and brain activities at resting state at baseline compared to after iTBS stimulation
Taipei Medical University Shuang Ho Hospital
Other
Cognitive Effects of Theta Burst Stimulation in Mild Cognitive Impairment and Alzheimer's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06367231
Alzheimer Disease, Brain Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT05477056
Alzheimer Disease, Brain Diseases
St Louis, Missouri, United States
View Trial DetailsNCT03682185
Aberrant Motor Behavior in Dementia, Alzheimer Disease
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05082883
Alzheimer Disease, Brain Diseases
Austin, Texas, United States
View Trial Details